Alto Neuroscience

ANROPhase 2

Los Altos, United StatesFounded 2019altoneuroscience.com

Alto Neuroscience is disrupting the trial-and-error approach in psychiatry by developing personalized medicines based on deep neurobiological insights. Built on 15 years of field-leading research, the company's clinical-stage pipeline targets core brain processes to help patients get better faster. Alto's precision approach uses brain biology measurements to predict clinical success and match patients with optimal treatments, offering a novel paradigm for treating serious mental health conditions.

Market Cap

$667.0M

Founded

2019

Focus

AI / Machine LearningDiagnosticsSmall Molecules

ANRO · Stock Price

USD 21.47+0.77 (+3.72%)

Historical price data

AI Company Overview

Technology Platform

Proprietary brain biomarker platform that measures brain biology to predict clinical response and identify patients most likely to benefit from specific drug candidates, enabling precision psychiatry.

Pipeline Snapshot

11 drugs in pipeline

Drug	Indication	Stage
Duloxetine + Bupropion	Major Depressive Disorder	Approved
Sertraline + Escitalopram	Major Depressive Disorder	Approved
ALTO-101 + Placebo	Schizophrenia	Phase 2
ALTO-100 + Placebo	Major Depressive Disorder	Phase 2
ALTO-100 + Placebo	Bipolar Disorder I or II With a Major Depressive Episode	Phase 2

Funding History

Total raised: $169M

IPO$129MUndisclosedFeb 2, 2024

Series A$40MApeiron Investment GroupJan 15, 2022

Opportunities

The global mental health treatment market represents a multi-billion dollar opportunity with significant unmet needs.

Alto's precision approach could capture market share by improving treatment response rates and reducing time to effective therapy.

Expansion into additional neuropsychiatric conditions and development of companion diagnostics present further growth avenues.

Risk Factors

Clinical trial failures, regulatory challenges for novel precision psychiatry approaches, competition from larger pharmaceutical companies, and slow adoption of biomarker-based treatment paradigms in psychiatry represent significant risks.

Financial sustainability depends on successful trial outcomes and additional funding.

Competitive Landscape

Competes with large pharma companies (Johnson & Johnson, Pfizer, AbbVie) and specialized biotechs (COMPASS Pathways, Sage Therapeutics) in neuropsychiatry. Alto differentiates through its biomarker-driven precision approach to patient stratification, aiming for higher response rates in targeted populations versus broad-spectrum therapies.

Publications

Patents

Pipeline